"psilocybe bohemica" stock
n the U.S.)
contribute to the therapeutic process; they may
even be the sole source for future progress.
Under these conditions, stereo music also
significantly deepened the intensity of the
experience. It appears that these kinds of specific
experiences may also account for the remarkable
success of treating terminal patients with LSD to
ease their fears in the face of death and to reduce
even the most severe forms of pain. In many such
cases, symptoms disappeared entirely, and relief
from pain and anxiety that continued even after the
drug's acute effects had worn off. A book by S.
Grof provides a compassionate analysis of such
successful treatments, which serves to underscore
the fact that systematic efforts to investigate these
particular therapeutic benefits have only just
begun.
So far, LSD has been the most widely
studied substance in terms of easing the suffering
of terminally ill patients, as well as dipropyltryptamine
(DPT), a synthetic drug structurally
similar to psilocybin that is active only when
administered by injection.
Below, a young woman from Switzerland
gives a detailed account of her second mushroom
experience. Her first experiment, with Psilocybe
cubensis, had already introduced her to the realm
of mystical experiences.
For her second journey,
she used 20 Psilocybe semilanceata mushrooms as
part of a group ritual and achieved transcendence.
A remarkable feature of her
account is that the presence of an experienced
guide was needed to realize the full potential of
this visionary quest.
"1 sat down next to another participant,
seeking to connect with others in preparation for
my journey. We proceeded to eat the fresh
mushrooms. The room grew quiet and lovely
music began to play. The mushrooms's effects
came on much faster than they did during my first
experiment. Twice I tried to establish closer
contact with my fellow participant, but he was
very nervous, and no source of reassurance for
me. I was seeking my spiritual companion, but did
not find that person among the present group. I
became a figure in a long, white robe, wandering
aimlessly among the columns (Greece?), still
searching.
My gaze lingered briefly on the wall next
to the door and I saw faces and figures appear
and vanish, but they did not hold my interest. It
was hopeless.
I continued my aimless roaming,
and I was on the material plane, which I wanted
to leave - had to leave.
Suddenly, I found myself
with one of the guides, who wanted to help me. I
stared off into the distance, longing to be free of
the material plane, but unable to do so. For a long
time, I failed to connect with the guide; our two
worlds were just too different.
Suddenly I sensed
that he wasn't able to look at me directly. The Psilocybe Azurescens Spore Print path
by which to reach me runs through my eyes,
because only they are truly alive. I asked
him to help me on my way and invited him to look
into my eyes. I felt as if all life energy was
draining from my bo xican mushroom species, so that
these materials need not be repeated in this
context. However, certain aspects concerning the
more recent uses of these mushrooms as well as
their conditions of growth will receive more
detailed attention in later chapters.
The main purpose of this book is to
inspire further study of these mushrooms,
particularly basic research efforts and medical
applications of magic mushroom ingredients.
The extensive bibliography will help
scientists and other interested mycophiles to
further immerse themselves in this complex area
of study.
Jochen Gartz
Figure 6 - Bronze doors with mushroom motif entitled "Trial and
Judgment" at Hildesheim Cathedral, Germany (ca. 1020).
CHAPTER 2
REFLECTIONS ON THE HISTORY
AND SCIENTIFIC STUDY OF MAGIC MUSHROOMS
It is remarkable that cultures native to the
American continent knew about a relatively large
number of natural mind-altering substances
compared to early cultures that evolved in Europe
or Asia. Botanical evidence does not support the
notion that Europe is home to fewer hallucinogenic
plants than other regions. Furthermore, the
growing number of recently discovered European
mushroom species containing psilocybin indicate a
flourishing psychotropic mycoflora in Europe
similar to those found in other countries.
It is unlikely that early European cultures
learned less about local plants and mushrooms
through usage and experience than cultures
elsewhere in the world. Most likely, early cultural
knowledge of European psychoactive plants and
mushrooms was lost or destroyed at some time in
history, probably as early as several hundred years
ago.
The discovery that the fly agaric
mushroom (Amanita muscaria) was known for its
psychoactive properties in Siberia invited the
conclusion that this mushroom was used as a
psychotropic agent in medieval Europe as well. In
fact, there is very little evidence from the Middle
Ages to indicate widespread knowledge of the
effects of specific mushrooms on human
consciousness. However, I believe that past reports
on psychoactive mushrooms were causally linked
to Amanita muscaria simply because this was the
only known psychotropic mushroom in Europe at
that time.
While the usage of Amanita muscaria
among Siberian tribes has generated reports of
spectacular hallucinations, European accounts of
fly agaric intoxications do not generally include
descriptions of such intensely hallucinatory
effects.
Accordingly, the potent hallucinogenic
effects of specific Psilocybes and related species
are likely to have had a much more significant
influence on early European cultures than the
delirium-like visions induced by Amanita
muscaria, a species that is also known to induce
unconsciousness and severe somatic side effects.
This hypothesis is corroborated by data from
comprehensive field studies conducted in Mexico.
I believe that historic accounts including those
described below - indicate a knowledge of
n the U.S.)
contribute to the therapeutic process; they may
even be the sole source for future progress.
Under these conditions, stereo music also
significantly deepened the intensity of the
experience. It appears that these kinds of specific
experiences may also account for the remarkable
success of treating terminal patients with LSD to
ease their fears in the face of death and to reduce
even the most severe forms of pain. In many such
cases, symptoms disappeared entirely, and relief
from pain and anxiety that continued even after the
drug's acute effects had worn off. A book by S.
Grof provides a compassionate analysis of such
successful treatments, which serves to underscore
the fact that systematic efforts to investigate these
particular therapeutic benefits have only just
begun. So far, LSD has been the most widely
studied substance in terms of easing the suffering
of terminally ill patients, as well as dipropyltryptamine
(DPT), a synthetic drug structurally
similar to psilocybin that is active only when
administered by injection.
Below, a young woman from Switzerland
gives a detailed account of her second mushroom
experience. Her first experiment, with Psilocybe
cubensis, had already introduced her to the realm
of mystical experiences. For her second journey,
she used 20 Psilocybe semilanceata mushrooms as
part of a group ritual and achieved transcendence.
A remarkable feature of her
account is that the presence of an experienced
guide was needed to realize the full potential of
this visionary quest.
"1 sat down next to another participant,
seeking to connect with others in preparation for
my journey. We proceeded to eat the fresh
mushrooms. The room grew quiet and lovely
music began to play. The mushrooms's effects
came on much faster than they did during my first
experiment. Twice I tried to establish closer
contact with my fellow participant, but he was
very nervous, and no source of reassurance for
me. I was seeking my spiritual companion, but did
not find that person among the present group. I
became a figure in a long, white robe, wandering
aimlessly among the columns (Greece?), still
searching.
My gaze lingered briefly on the wall next
to the door and I saw faces and figures appear
and vanish, but they did not hold my interest. It
was hopeless. I continued my aimless roaming,
and I was on the material plane, which I wanted
to leave - had to leave. Suddenly, I found myself
with one of the guides, who wanted to help me. I
stared off into the distance, longing to be free of
the material plane, but unable to do so. For a long
time, I failed to connect with the guide; our two
worlds were just too different. Suddenly I sensed
that he wasn't able to look at me directly. The path
by which to reach me runs through my eyes,
because only they are truly alive. I asked
him to help me on my way and invited him to look
into my eyes. I felt as if all life energy was
draining from my bo Most recreational users of Psilocybe cubensis (when grown in vitro) require a dosage of 1 to 2 gm of dried mushrooms to produce an altered state of consciousness; a clinical dosage for Psilocybe cubensis, on the other hand, had previously been reported as ranging from 3 to 5 gm of dried material. This dosage would be comparable to the amount of fungal material consumed for religious purposes in a Mazatec Indian healing and curing ceremony. In 1982, one research team "found that the level of psilocybin and psilocin varies over a factor of 4 among various in vitro cultures of Psilocybe cubensis, while specimens from outdoors varied tenfold." A fresh dosage of Psilocybe cubensis in Australia would be approximately from 1 to 2 large mushrooms weighing up to as much as one fresh ounce, or as many as from 25 to 50 small mushrooms equaling the same weight amount. Ethnopharmacologist Jonathan Ott (1976, 1993) noted that he has observed "the ingestion of from 0.5 gm to 5.9 gm dried weight (10 gm to 40 gm fresh)", of various species of Psilocybe. Dosage for Psilocybe subcubensis would be the same as for Psilocybe cubensis. Both of these latter two species are macroscopically alike. The usual dosage for Copelandia cyanescens required to induce psychedelic visual effects ranges from 1 to 3 large specimens (cap diameter c. 5 mm), or as many as 5 to l0 medium-sized mushrooms (cap diameter c. 2.5 mm); however, personal tolerance to this species may occur with continued use, and some who consume large amounts of this mushroom have reportedly ingested as many as 50 to 200 fresh specimens of various sizes.
new
new mushrooms mushrooms
new
The Mazatec Indians, who have a long tradition of using the mushrooms, inhabit a range of mountains called the Sierra Mazateca in the northeastern corner of the Mexican state of Oaxaca. The shamans in this essay are all
Gymnopilus sp. natives of the town of Psychedelic Mushroom Identification Kansas Huautla de Jimenez. Properly speaking they are Huautecans; but since the language they speak has been vitro in cyanescens in called Mazatec and they have been referred to in the previous anthropological literature as Mazatecs, I have retained that name, though strictly speaking, Mazatecs are the inhabitants of the village of Mazatlan in the same mountains.
Mind-altering
"psilocybe bohemica" stock (psilocybine containing) mushrooms have
"psilocybe bohemica" stock
been
"psilocybe bohemica" stock
Newzealandmagicmushrooms traditionally used in
"psilocybe bohemica" stock religious healing and
"psilocybe bohemica" stock curing ceremonies by native
There are
Psilocybinpsilocinromania more than 1 dozen species of "magic mushrooms" in Australia and New Zealand. Four of these species are dung (manure) inhabiting mushrooms. They include Psilocybe cubensis and/or Psilocybe subcubensis (known locally as "gold caps" and/or "gold tops"), Psilocybe subaeruginosa, and Copelandia cyanescens (the latter is known locally as "blue meanies"). These four species contain the mind altering alkaloids psilocybine and psilocine and are the most common hallucinogenic mushrooms in Australia. In New Zealand, the most commonly used species are Copelandia cyanescens and Psilocybe semilanceata, the latter species is recognized throughout the world as the "liberty cap").
This species only occurs in manured soil and does not grow directly from the dung of cattle, sheep or other four legged farm animals. Psilocybe cubensis the most popular of these species, is well known throughout much of the world; however, this species is not known to occur in New Zealand. Other species described in this guide are known to occur in manured soil, in pastures, meadows, grazing lands, some lawns and in the bark mulch and woodchips of deciduous woods.
ulinary
mushroom bears no
resemblance, either in size or form, to Inocybe
aeruginascens. Overall, however, these
unfortunate cases have also contributed to our
understanding of mushroom biochemistry.
In this context, I want to emphasize
once more that the hallucinogenic varieties
among the Inocybes can easily be mistaken for
those muscarine-producing Inocybe species
that are extremely poisonous.
As part of his investigation of the
Psilocybe genus, Guzman noted a common
trait among the hallucinogenic species, in
addition to the bluing reaction: a flour-like
smell or taste. Apart from the inherent
subjective nature of our sense of smell and
taste, a common odor is a trait that definitely
does not apply to the European species (also
see Chapter 3.2).
Mycophile or Mycophobe?
There are reports from the Western
United States about people with expert
knowledge of Psilocybe semilanceata -
devoted mushroom hunters who can identify
the species with drill and accuracy. At the
same time, however, these experts cannot
identify easily spotted common table
mushrooms, nor are they able to differentiate
the Agaricus species (champignons) from other
mushrooms, even when these species grow on
the same pasture. Such individuals, then, are
not interested in species other than Psilocybe
semilanceata. In my opinion, this attitude
reflects a rare combination of mycophilia and
mycophobia.
A mushroom's spore dust provides
important information needed to determine
identity. A spore print is left by the gills when
the cap is placed on black or white paper
(depending on spore color). As the process
takes several hours, a glass vessel must be
placed over the cap to prevent drying. While
useful, information obtained from spore
analyses has its limitations, For instance,
spores derived from mushrooms belonging to
different genera may have the same color, but
reveal basic differences under the microscope.
There is also a high degree of similarity among
spores from different Psilocybe species. Thus,
the only way to prevent grave errors and
potentially deadly intoxications is to rely on
experienced experts for mushroom
identification, a process that must include
analysis of available ecological data.
CHAPTER 5
THE BLUING PHENOMENON AND METOL
TESTING: REALITY VS. WISHFUL THINKING
As previously discussed in Chapters 3.1
and 3.7, the bluing reaction is characteristic
of species that produce psilocybin. Still, for
unknown reasons, some species or samples
belonging to a genus that usually turns blue
may not always change color, regardless of
psilocybin content. Among the species that I
have examined, Psilocybe bohemica
displayed the most impressive bluing
reaction. The caps of this species stain very
quickly in reaction to pressure. Other species,
such as Psilocybe cubensis (Earle) Sing.
have stems that develop very intensely blue
stains, while their caps do not exhibit the
bluing reaction. By contrast, Psilocybe
As they say, ʼTis the season to be pickingʼ, but make e creek on wood chips of
Carpinus, Alnus and Salix, on raw compost
mixtures of Picea, Pinus and Larix needles,
as
Sept. Oct. Nov. Dec. Jan.
Figure 21 - Fruiting curve of Psilocybe
cyanescens based on observations at several
locations in the former Czechoslovakia.
The mycelia make use of different kinds
of plant debris and even grow on wet cardboard,
where they develop into rhizomorphs just like
they would in nature. Rhizomorphs are thick
strands of mycelia that serve to transport
nutrients and water. They also develop intense
blue stains (see Figure 22).
Figure 23
Distribution pattern of Psilocybe
cyanescens in Germany and adjacent areas
(according to Krieglsteiner). Locations are
indicated by black dots.
Figure 22
Psilocybe bohemica
rhizomorphs growing on
wet cardboard.
Figure 24 - Psilocybe cyanescens at a natural location (USA).
Figure 25 - Psilocybe bohemica on twigs and leaves.
Impressive Experiences
Psilocybe bohemica is a very psychoactive
species. Its effects are vividly documented in the
following account of one natural scientist's
experience as part of controlled clinical trials in
Prague:
About 30 mg of psilocybin in mushroom
tissue was prepared in hot water, with effects
already noticeable ten minutes after ingestion. I
grew increasingly quiet. At first, my legs began to
tingle, then my underarms as well. Aside from a
deeper breathing rhythm, few other somatic effects
were noted. Initially there were fits of laughter
caused by unusual cognitive associations; this
laughter also affected the two "sober" guides. A
growing hyperacuity interfered with the ability to
listen to music, so that Vivaldi's "Springtime"
caused painful stabs inside the brain. I compared
the pain to that caused by a "sawing knife". The
experimenters appeared bloated and yellow...
Existing bodily characteristics, such as thinning
hair stimulated a person's illusionary
transformation into a monk with tonsure. Their
voices also appeared reverent and, from a
somewhat paranoid point of view, these gentlemen
at times seemed to be working a switching station
that, for some reasons, was my enemy. At the same
time, I found both of them to be quite likeable.
During this time period, the other female subject
perceived fantastic images of moving colors and
saw visions of her whole life unfolding behind
closed eyes. During this period, I had the distinct
impression that an electrical current was flowing
through my body, which was not an uncomfortable
sensation. About three hours later, the gentlemen
retired to the kitchen and the nature of the
experience changed quite drastically.
At first I felt as if my legs were increasingly
merging into the wall, a very comfortable
experience. In a state of utter clarity of
consciousness, I finally felt as if I had no body at all.
I said. "The most descriptive expression is the
experience of a pure soul". Using words as triggers,
we were able to induce shared experiences o
Psilocybin Tee Shirts
JOCHEN GARTZ
MAGIC MUSHROOMS
Around the World
A Scientific Journey Across Cultures and
Time
The Case for Challenging Research
and Value Systems
* LIS PUBLICATIONS * LOS ANGELES, CA*
Figure 1 - Water Color Painting of Psilocybe semilanceata
(Germany, 1927)
TABLE OF CONTENT (With Active Links' Just Click On A Subject To Go To The Page)
"Who Was the First Magician?" - Foreword by Christian Ratsch 7
1. Introduction 9
2. Reflections on the History and Scientific Study of Magic Mushrooms 10
3. The Current State of Knowledge About European Species 14
3.1 Psilocybe semilanceata: The Classic Species Among European Psychotropic Mushrooms 16
3.2 Psilocybe cyanescens: Potent Mushrooms Growing on Wood Debris 29
3.3 Panaeolus subbalteatus: Mycology and Myths about the Panaeolus Species 37
3.4 Inocybe aeruginascens: Fast-Spreading New Arrivals 44
3.5 Gymnopilus purpuratus: Magnificent Mushrooms from South America 51
3.6 Conocybe cyanopus: Tiny Mushrooms of Remarkable Potency 55
3.7 Pluteus salicinus: A Little-known Wood-Inhabiting Species 58
4. Mushroom Identification: Taxonomic Confusion and the Potential for Deadly Mistakes 61
5. The Bluing Phenomenon and Metol Testing: Reality vs. Wishful Thinking 63
6. Mushroom Cultivation: Classic Findings and New Techniques 66
7. Psychotropic Mushroom Species Around the World 77
7.1 Spotlight on North America and Hawaii 79
7.2 Mycophilia in Central and South America 82
7.3 Australia's Mycoflora Attracts Attention 84
7.4 European Customs and Conventions 87
7.5 Japanese Experimentation 93
7.6 Intoxications and the Oldest Known Mushroom Cult in Africa 95
7.7 Usage in Southeast Asia and the South Pacific Islands 98
8. Some Comments on Effects of Mushrooms from the Category Phantastika 102
9. Psychotherapy 108
10. Outlook 114
11. Bibliography 120
Index 129
Figure 2 - Psilocybe cubensis from Australia
Figure 3 - Water color painting of Panaeolus subbalteatus (Germany, 1927).
Figure 4 - Fresh Panaeolus subbalteatus mushrooms.
FOREWORD
Nobody knows precisely when the first magic
mushroom emerged from the shadows of
prehistory to enter the light of consciousness.
Nobody knows when the first magic mushroom
was eaten by a human being. Nobody knows
just who the first magic mushroom eater was. In
seeking answers to these questions, we can only
speculate. Mycophobes, however, are quick to
voice their conviction that only a fool would be
reckless enough to want to attain a higher state
of consciousness beyond the boundaries of
everyday reality. And only a fool would attempt
to do this by ingesting those odd little things that
mysteriously thrive on decaying, humid soil,
rotten wood and malodorous mounds of cow
manure.
Historically, magic, mushrooms have
been feared and hated` since antiquity: magic
mushrooms were thought to be made from
poisons that had dripped from serpents' fangs;
they were considered to be unclean emissions of
evil spirits; moreover, mushrooms were a kn n the U.S.)
contribute to the therapeutic process; they may
even be the sole source for future progress.
Under these conditions, stereo music also
significantly deepened the intensity of the
experience. It appears that these kinds of specific
experiences may also account for the remarkable
success of treating terminal patients with LSD to
ease their fears in the face of death and to reduce
even the most severe forms of pain. In many such
cases, symptoms disappeared entirely, and relief
from pain and anxiety that continued even after the
drug's acute effects had worn off. A book by S.
Grof provides a compassionate analysis of such
successful treatments, which serves to underscore
the fact that systematic efforts to investigate these
particular therapeutic benefits have only just
begun. So far, LSD has been the most widely
studied substance in terms of easing the suffering
of terminally ill patients, as well as dipropyltryptamine
(DPT), a synthetic drug structurally
similar to psilocybin that is active only when
administered by injection.
Below, a young woman from Switzerland
gives a detailed account of her second mushroom
experience. Her first experiment, with Psilocybe
cubensis, had already introduced her to the realm
of mystical experiences. For her second journey,
she used 20 Psilocybe semilanceata mushrooms as
part of a group ritual and achieved transcendence.
A remarkable feature of her
account is that the presence of an experienced
guide was needed to realize the full potential of
this visionary quest.
"1 sat down next to another participant,
seeking to connect with others in preparation for
my journey. We proceeded to eat the fresh
mushrooms. The room grew quiet and lovely
music began to play. The mushrooms's effects
came on much faster than they did during my first
experiment. Twice I tried to establish closer
contact with my fellow participant, but he was
very nervous, and no source of reassurance for
me. I was seeking my spiritual companion, but did
not find that person among the present group. I
became a figure in a long, white robe, wandering
aimlessly among the columns (Greece?), still
searching.
My gaze lingered briefly on the wall next
to the door and I saw faces and figures appear
and vanish, but they did not hold my interest. It
was hopeless. I continued my aimless roaming,
and I was on the material plane, which I wanted
to leave - had to leave. Suddenly, I found myself
with one of the guides, who wanted to help me. I
stared off into the distance, longing to be free of
the material plane, but unable to do so. For a long
time, I failed to connect with the guide; our two
worlds were just too different. Suddenly I sensed
that he wasn't able to look at me directly. The path
by which to reach me runs through my eyes,
because only they are truly alive. I asked
him to help me on my way and invited him to look
into my eyes. I felt as if all life energy was
draining from my bo by A. Hofmann, Sandoz Pharmaceuticals
manufactured about 2 kg (ca. 4.4lbs) of
pure psilocybin for scientific research purposes.
The results of pharmacological testing
soon revealed psilocybin as an alkaloid that was
perfectly safe for human subjects under controlled
experimental conditions. Despite this evidence, the
anti-drug legislative framework of the mid1960s
firmly established an "official mycophobia", a
misguided, yet entrenched policy that still prevails
today and effectively prevents the scientific
investigation of promising potential applications
for psilocybin and other alkaloids. At the same
time, mycological and biochemical
research studies have shown that psilocybincontaining
mushrooms thrive all over the world
and can be found on all continents. These
mushrooms are no different from any other
mycoflora and must not be excluded from
scientific investigation because of their alkaloid
content.
In addition to overall variations in value
systems across cultures, individuals tend to
develop their own personal attitudes towards
mushrooms in general. Oftentimes, the evolution
of specific opinions about mushrooms can be
traced back to childhood events, even though such
early experiences seldom account for the
development of prevailing biases and value
systems later in life.
I recall an incident from my own
childhood, which occurred when I was about five
years old. I was playing in a grassy meadow, when
a girl pointed to a brown mushroom and earnestly
explained that it was inedible and poisonous.
While I have never forgotten this encounter, I did
grow up to become a devoted mushroom
enthusiast. On the other hand, a different
childhood event has left me with the vivid memory
of discovering a landfill virtually covered with
vast numbers of gilled bluing mushrooms and the
sense of awe I experienced contemplating this
sight. In general, the unusual characteristics of
these mushrooms are most likely responsible for
strong impressions formed early in life, which then
may develop into various attitudes or beliefs later
on.
An enduring personal interest in
psychotropic mushroom species can serve to
amplify or diminish mycophobic as well as
mycophilic dispositions, depending on the
influence of other factors. After all, judgments
about the benefit or folly of deliberately altering
one's state of consciousness are also colored by
individual preferences, biases and opinions.
The following chapters are meant to
illustrate this diversity of attitudes towards
psychotropic mushrooms. Descriptions of planned
and involuntary experiments with specific
mushroom species offer convincing evidence that
the effects of psychoactive mushrooms are open to
many possible interpretations.
CHAPTER 3
THE CURRENT STATE OF KNOWLEDGE ABOUT
EUROPEAN SPECIES
Figure 7 - Distribution pattern of Psilocybe cyanescens across Europe and North Africa
(according to Krieglsteiner). Black dots indicate approximate locatio It has been suggested by an Australian physician that the general public in Australia, as well as members of its drug using subculture, first became aware of the visionary properties of these psychoactive mushrooms by a visiting surfer(s), who came from either New Zealand or the United States (Hawaii) and most likely provided ethnomycological information to local surfers (McCarthy, 1971). This physician reported that the use of psychoactive mushrooms, as well as 21 other drugs "was well demonstrated during a survey on drug abuse that was conducted in Southern Queensland during l969." This survey relied on interviews of 51 people belonging to "the `surfer' subculture local beach resorts".
In this report, the doctor believed that "although the survey involved surfers and their female friends, there is Cubensis Season Texas no suggestion that the use of these drugs is confined to this group, which constitutes but a proportion of our (Australian)
"psilocybe bohemica" stock
young drug taking community." It is thus likely that word-of-mouth communication made a significant contribution to the increasing use of "magic mushrooms" in Australia and NZ. The question of dosage is often confused by the variation in the source of the hallucinogenic mushroom species which is consumed. a have been reported from
the following countries: Finland, Norway,
Sweden, Denmark, Germany, Switzerland,
Austria, The Netherlands, Belgium, France,
Russia, Poland, the former Czechoslovakia,
Hungary, Romania, Scotland, England, Wales,
Italy and Spain.
Unfortunately, there are no comprehensive
maps detailing the species's
distribution pattern. Traditionally, mycologists
have often neglected relatively tiny species, such
as Psilocybe semilanceata, that tend to share their
habitats with other, more prominent species. The
sarcastic phrase "The mushrooms occur in
abundance wherever mycologists abound" is
particularly pertinent in reference to the Psilocybe
species. Prior to the discovery of psilocybin, the
Psilocybe genus languished in the literature,
shrouded in obscurity. To this day, few
189. Psilocybe semilanceata Fr. Worthless]
The cap is uniformly conic to bell-shaped, with a pointy or obtuse center forming
an almost wart-like protrusion; initially, caps are often taller than they are wide, margins
are bent and curved inward; later on, width of cap is 1.5-4 cm. Hygrophanous; coloration
is a dirtyish olive-brown when wet, with translucent striate margins; at the center,
coloration is ocher or greenish-yellow against an overall shade of smudgy pale yellow and
oftentimes some greenish stains; only the margins are banded by a darkcolored, watery
stripe around the edge. No stripes or banding evident when mushrooms are completely
dried. Lacking a veil, caps are thin-fleshed, bald, with an easily separable pellicle that
remains gelatinous-sticky for a long time, turning shiny when dry.
Gills are olive brown to blackish purple brown in color, with the edges often
remaining white, gill spacing is quite crowded; gill attachment is either roughly linear or
mostly adnexed; up to 3.5 mm wide; attached at the stem only, fully detached later on.
Spores are elongated to ellipitical in shape, smooth and large, measuring 12-16 u
by 6-8,u. Color of spore dust is blackish purple brown.
Stem is very slender, almost uniformly thin and always twisted, 6-12 cm long and
1.25-2 mm thick, yellowish or whitish in color; areas subjected to pressure develop bluishgreen
stains. Stems are silky smooth and roughly at the center, cortinate fibrils appear like
remnants of a veil, which is brittle and lined with a white fibrous cord of wool-like
texture.
When dry, the flesh of the cap is colored pale yellow, while the stem's flesh is
ocher brown in color, especially towards the bottom. It is odorless and its flavor is mild.
The mushroom grows from August to October, frequently in gregarious clusters, and can
be found in pastures and along roadways, growing on dung that has undergone complete
decomposition. It is not a particularly rare species.
Figure 11(above) This excellent description of Psilocybe semilanceata by Michael & Schulz
(1927) is shown here as originally published in German, with an English translation.
Mycologists sp
mushroom southeast texas @ 8/1/2010 2:02:12 AM